I’ve gotten a big pile of questions about the latest teaser pitch from Jeff Brown, who is now taking credit for the rise of the CRISPR stocks and sees another big surge coming. And for what it’s worth, he was one of the early newsletter guys promoting the three primary CRISPR stocks a few years […]
Articles
This article was originally published on November 5, 2018, we’re getting lots of questions so we’re popping it to the top of the page for you but it has not been updated or revised — the ad being covered appears to be almost identical to the ad that was running in the fall of 2018. […]
“This Wednesday, September 5 Tuesday, May 28, a group of scientists will take the stage at a prestigious medical conference… “And announce to the world the potential end of disease as we know it.” That’s the attention-getting part of Ray Blanco’s latest teaser ad for his FDA Trader newsletter that Gumshoe readers have been asking […]
Here’s a bit from the email that Matt McCall sent out introducing his lastest teaser ad: “When it comes down to it, there are really just three ways to get truly rich in the stock market. You can put thousands into the market every year, hold for decades, and retire with a fortune. You can […]
Matt McCall is pitching a “$200 into $1 million” stock idea as he tries to drum up subsribers for his NexGen Investor… and that sounds fun, right, owning a stock that goes to a million dollars per share? It probably won’t happen, of course, and I don’t know how many times it might have actually […]
This piece originally appeared as part of the Friday File for the Irregulars on July 28, but has now been unlocked for everyone. The company reported quarterly results about two weeks ago that were generally well received, and has otherwise gotten more positive press and analyst upgrades over the past month, and the shares are […]
The article below was originally published on November 27, 2017, when Jeff Brown’s ads promoting the “God Key” started to show up in our inboxes. It has not been updated or revised, but the new versions of the ad from Brown are very similar to the ones we covered in November, including the description of […]
Jason Stutman has a teaser pitch going around for his Technology & Opportunity newsletter (currently $99), and the bait for us is that he’s promising a company that will get you rich as Monsanto dies. Lots of folks have a deep hatred for Monsanto, of course, both because of anti-GMO fear and Roundup resistance/overuse/drift/cancer risk […]
Fear Of Missing Out is such a big deal that it gets its own acronym in my book (FOMO — and a clever FOMO-fueling website here), and it drives investors to take huge chances just so they don’t have to worry about missing a chance at stupendous gains. That’s what many newsletter ads use to […]
Comments
We keep seeing this ad and getting more questions about it -- the ad hasn't changed in any big way that I've noticed, th...
I've often wondered how companies that develop something that eliminates disease, such as this, will make money. The OUT...
$12 trillion? That's over half of the US economy. Even over 10 years, it's never going to happen. I guess for $79/yea...
Well I just hope this is a boomer like the "God Key" stocks (EDIT, CRSP) which are about 50% lower from their peaks in 2...
Although the last three months is a short time period, it's the only one I could research easily. Over that period, the...
I think its cell data. https://www.investors.com/news/technology/crispr-gene-editing-biotech-companies/ https://mo...
There've been a lot of uncertainties around the CRISPR companies, but I think right now the elephant in the room is the ...
Found the article I remember that talks about the patent license. https://www.forbes.com/sites/matthewherper/2015/08/10/...
Amazing how they can predict uranium demand (prices) over the next 15 years or more. After you've spent about $75,000-$...
Thanks for putting everything into perspective. I read about "exciting new developments" every day, and it is impossibl...
I bought CRSP and I am up over 60%. Might think about the other two as well. This technology will take some time to deve...
I gave up on EDIT, NTLA, and CRSP and went with Illumina, Inc. (ILMN) which is similar but much less volatile. And ILMN ...
If you read all the way down to the end of Altucher's epic screed you see that he says you should buy all three: EDIT, N...
I have a really hard time with R&D companies or very early-stage clinical biotechs -- partly because it's an end market ...